Akcea Therapeutics Receives Orphan Designation in Europe for Volanesorsen for the Treatment of Familial Partial Lipodystrophy (FPL)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/12/2026

1. SKHY
2. USO
3. SPY
4. META
5. DAL
6. PEP
7. SKHYV
8. ALP
9. NRIX
10. KBH

Go back to Akcea Therapeutics Receives Orphan Designation in Europe for Volanesorsen for the Treatment of Familial Partial Lipodystrophy (FPL)

Ionis Pharmaceuticals (IONS) PT Raised to $64 at Needham & Company as ENDEAR Study Halted Early for Efficacy

August 1, 2016 12:20 PM EDT

Needham & Company analyst Chad Messer reiterated a Buy rating and lifted its price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $64.00 (from $55.00) after the company and Biogen announced the pivotal ENDEAR study of nusinersen in infants with spinal muscular atrophy (SMA) met its primary endpoint... More